1.Caplan, LR. Treatment. In Caplan’s Stroke, a clinical approach, 4th edition. Saunders-Elsevier, Philadelphia, 2009, pp. 146–217.
2.Caplan, LR, Sergay, S. Positional cerebral ischemia. J Neurol Neurosurg Psychiatry 1976;39:385–391.
3.Toole, J. Effects of change of head, limb, and body position on cephalic circulation. N Engl J Med 1968; 279:307–311.
4.Wojner-Alexander, AW, Garami, Z, Chernyshev, OY, Alexandrov, AV. Heads down: flat positioning improves blood flow velocity in acute ischemic stroke. Neurology 2005;64;1354–1357.
5.Rordorf, G, Cramer, SC, Efird, JT, Schwamm, LH, Buonanno, F. Koroshetz, WJ. Pharmacological elevation of blood pressure in acute stroke. Clinical effects and safety. Stroke 1997;28:2133–2138.
6.Hillis, AE, Ulatowski, JA, Barker, PB, Torbey, M, Ziai, W., Wityk, RJ. A pilot randomized trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke. Cerbrovasc Dis 2003;16(3):236–246.
7.Chalela, JA, Dunn, B, Todd, JW, Warach, S. Induced hypertension improves cerebral blood flow in acute ischemic stroke. Neurology 2005;64:1979.
8.Hillis, AE, Kane, A, Tufflash, E, Ulatowski, JA, Barker, PB, Beauchamp, NJ, Wityk, RJ. Reperfusion of specific brain regions by raising blood pressure restores selective language functions in subacute stroke. Brain Lang 2001;79:495–510.
9.Hammer, M, Jovin, T, Wahr, J, Heiss, WD. Partial occlusion of the descending aorta increases cerebral blood flow in a non-stroke porcine model. Cerebrovasc Dis 2009;28:406–410.
10.Liebeskind, DS. Aortic occlusion for cerebral ischemia: from theory to practice. Curr Cardiol Rep 2008;10:31–36.
11.Simeone, FA. Enhancement of cerebral flood flow by intermittent aortic occlusion. Eur Neurol 1972;8:142–144.
12.Shuaib, A. Bornstein, N, Diener, H-C et al. for the SENTIS Investigators. Partial aortic occlusion for cerebral perfusion augmentation. Safety and Efficacy of Neuroflo in Acute Ischemic Stroke Trial. Stroke 2011;42:1680–1690.
13.Collen, D. On the regulation and control of fibrinolysis: Edward Kowalski Memorial Lecture. Thromb Haemost 1980; 43:77–89.
14.Sloan, MA. Thrombolysis and stroke, past and future. Arch Neurol 1987; 44:748–768.
15.del Zoppo, GJ, Hosomi, N. Mechanisms of thrombolysis. In Lyden, PD (ed.), Thrombolytic therapy for acute stroke. Humana Press, Totowa, NJ, 2005, pp. 3–27.
16.del Zoppo, GJ. Thrombolytic therapy in cerebrovascular disease. Stroke 1988; 19:1174–1179.
17.Pessin, MS, del Zoppo, GJ, Furlan, AJ. Thrombolytic treatment in acute stroke: review and update of selected topics. In Cerebrovascular diseases, 19th Princeton Conference, 1994. Butterworth-Heinemann, Boston,1995; pp. 409–418.
18.The National Institute of Neurological Disorders and Stroke rt-PA Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587.
19.Hacke, W, Kaste, M, Fieschi, C et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274:1017–1025.
20.Hacke, W, Kaste, M, Fieschi, C et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS ll). Lancet 1998;352:1245–1251.
21.Clark, WM, Wissman, S, Albers, GW et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial. Alteplase Thrombolysis for Acute Non-interventional Therapy in Acute Stroke. JAMA 1999 282:2019–2026.
22.ATLANTIS, ECASS, and NINDS rt-PA Study group Investigators. Association of outcome with early stroke treatment. Pooled analysis of the ATLANTIS, ECASS, and NINDS stroke trials. Lancet 2004;363: 768–774.
23.Furlan, AJ, Higashida, RT, Wechsler, L et al. PROACT II. Intra-arterial pro-urokinase for acute ischemic stroke. A randomized controlled trial. JAMA 1999;282;2003–2011.
24.Hacke, W, Zeumer, H, Ferbert, A, Bruckmann, H, del Zoppo, G. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 1988;19:1216–1222.
25.Caplan, LR. Treatment. In Caplan’s Stroke, a clinical approach, 4th edition. Saunders-Elsevier, Philadelphia, 2009, pp. 156–168.
26.Grond, M, Rudolf, J, Schmulling, S, Stenzel, C, Neveling, M, Heiss, W-D. Early intravenous thrombolysis with recombinant tissue-type plasminogen activator in vertebrobasilar ischemic stroke. Arch Neurol 1998;55:466–469.
27.Montavont, A, Nighoghossian, N, Derex, L et al. Intravenous r-tPA in vertebrobasilar acute infarcts. Neurology 2004;62:1854–1856.
28.Sarikaya, H, Arnold, A, Engelter, S et al. Outcomes of intravenous thrombolysis in posterior versus anterior circulation stroke. Stroke 2011;42:2498–2502.
29.Lindsberg, P, Soinne, L, Tatlisumak, T et al. Long-term outcome after intravenous thrombolysis of basilar artery occlusion. JAMA 2004;292:1862–1866.
30.Bhatia, R, Hill, M, Shobha, N et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke. Stroke 2010;41:2254–2258.
31.Pagola, J, Ribo, M, Alvarez-Sabin, J et al. Thrombolysis in anterior versus posterior circulation strokes: timing of recanalization, ischemic tolerance, and other differences. J Neuroimaging 2011;21:108–112.
32.Sairanen, T, Strbian, D, Soinne, L et al. for the Helsinki Stroke Thrombolysis Registry (HSTR) Group. Intravenous thrombolysis of basilar artery occlusion. Predictors of recanalization and outcome. Stroke 2011;42:2175–2179.
33.Mendonça, N, Rodriguez-Luna, D, Rubiera, M et al. Predictors of tissue-type plasminogen activator nonresponders according to location of vessel occlusion. Stroke 2012;43:417–421.
34.Caplan, LR. Thrombolysis in vertebrobasilar occlusive disease In Lyden, PD (ed.), Thrombolytic therapy for acute stroke, 2nd edition. Humana Press, Totowa, NJ, 2005, pp. 203–209.
35.Mobius, E, Berg-Dammer, E, Kuhne, D, Nahser, HC. Local thrombolytic therapy in acute basilar artery occlusion. Experience with 18 patients. In Hacke, W, del Zoppo, GJ, Hirschberg, M (eds.), Thrombolytic therapy in acute ischemic stroke. Springer, Heidelberg, 1991, pp. 213–215.
36.Brandt, T, von Kummer, R, Muller-Kuppers, M, Hacke, W. Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome. Stroke 1996:27:875–881.
37.Wijdicks, EFM, Nichols, DA, Thielen, KR et al. Intra-arterial thrombolysis in acute basilar artery thromboembolism: the initial Mayo Clinic experience. Mayo Clin Proc 1997;72:1005–1013.
38.Cross, DT, Moran, CJ, Akins, PT, Angtuaco, E, Diringer, MN. Relationship between clot location and outcome after basilar artery thrombosis. AJNR Am J Neuroradiol 1997;18:1221–1228.
39.Mitchell, PJ, Gerraty, RP, Donnan, GA et al. Thrombolysis in the vertebrobasilar circulation: the Australian Urokinase Stroke Trial. Cerebrovasc Dis 1997;7:94–99.
40.Egan, R, Clark, W, Lutsep, H, Nesbit, G, Barnwell, S, Kellogg, J. Efficacy of intraarterial thrombolysis of basilar artery stroke. J Stroke Cerebrovasc Dis 1999;8:22–27.
41.Eckert, B, Kucinski, T, Pfeiffer, G, Groden, C, Zeumer, H. Endovascular therapy of acute vertebrobasilar occlusion: early treatment onset as the most important factor. Cerebrovasc Dis 2002;14:42–50.
42.Jung, S, Mono, M-L, Fischer, U et al. Three-month and long term outcomes and their predictors in acute basilar artery occlusion treated with intra-arterial thrombolysis. Stroke 2011;42:1946–1951.
43.Karameshev, A, Arnold, M, Schroth, G et al. Diffusion-weighted MRI helps predict outcome in basilar artery occlusion patients treated with intra-arterial thrombolysis. Cerebrovasc Dis 2011;32:393–400.
44.Macleod, MR, Davis, SM, Mitchell, PJ et al. Results of a multicentre randomized controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke. Cerebrovasc Dis 2005;20:12–17.
45.Becker, KJ, Monstein, LH, Ulatowski, Mirski M, Williams, M, Hanley, DF. Intraarterial thrombolysis in vertebrobasilar occlusion. Am J Neuroradiol 1996;17:255–262.
46.Meier, N, Fischer, U, Schroth, G et al. Outcome after thrombolysis for acute posterior cerebral artery occlusion. Cerebrovasc Dis 2011;32:79–88.
47.Barlinn, K, Becker, U, Puetz, V et al. Combined treatment with intravenous abciximab and intraarterial tPA yields higher recanalization rate in patients with acute basilar artery occlusion. J Neuroimag 2012;22:167–171.
48.Pfefferkorn, T, Holtmannspötter, M, Schmidt, C et al. Drip, ship, and retrieve. Comparative recanalization therapy in acute basilar artery occlusion. Stroke 2010;41:722–726.
49.Nagel, S, Schellinger, PD, Hartmann, M et al. Therapy of acute basilar artery occlusion. Intraarterial thrombolysis alone vs bridging therapy. Stroke 2009;40:140–146.
50.Nakayama, T, Tanaka, K, Kaneko, M, Yokoyama, T, Uemura, K. Thrombolysis and angioplasty for acute occlusion of intracranial vertebrobasilar arteries. J Neurosurg 1998;88:919–922.
51.Lin, R, Aleu, A, Jamkowitz, B et al. Endovascular revascularization of chronic symptomatic vertebrobasilar occlusion. J Neuroimaging 2012;22:74–79.
52.Saver, JL. Mechanical thrombectomy devices for treatment of stroke. Neurol Clin Pract 2012;1: 231–234.
53.Smith, WS, Sung, G, Saver, JL et al. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi Merci trial. Stroke 2008;39:1205–1212.
54.Penumbra Pivotal Stroke Trial Investigators. The PENUMBRA pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large artery occlusive disease. Stroke 2009;40:2761–2768.
55.Roth, C, Mielke, A, Siekmann, R, Ferbert, A. First experience with a new device for mechanical thrombectomy in acute basilar artery occlusion. Cerebrovasc Dis 2011;32:28–34.
56.Henkes, H, Flesser, A, Brew, S et al. A novel microcatheter-delivered highly-flexible and fully-retrievable stent specifically designed for intracranial use. Interv Neuroradiol 2003;9:391–393.
57.Jankowitz, B, Aleu, A, Lin, R et al. Endovascular treatment of basilar artery occlusion by manual aspiration thrombectomy. J Intervent Surg 2010; 2:110–114.
58.Imparato, AM. Vertebral artery reconstruction: a nineteen-year experience. J Vasc Surg 1986;2:626–634.
59.Spetzler, RF, Hadley, MN, Martin, NA et al. Vertebrobasilar insufficiency: I. Microsurgical treatment of extracranial vertebrobasilar disease. J Neurosurg 1987;66:648–661.
60.Kieffer, E, Koskas, F, Bahnini, A et al. Long-term results after reconstruction of the cervical vertebral artery. In Caplan, LR, Shifrin, EG, Nicolaides, AN, Moore, WS (eds.), Cerebrovascular ischaemia: investigation and management. Med-Orion, London, 1996, pp. 617–625.
61.Berguer, R., Flynn, L.M., Kline, R.A. Caplan, L.R. Surgical reconstruction of the extracranial vertebral artery: Management and outcome. J Vasc Surg 2000;31:9–18.
62.Haghighi, Ab, Edgell, RC, Cruz-Flores, S, Zaidat, OO. Vertebral artery origin stenosis and its treatment. J Stroke Cerebrovasc Dis 2011;20:369–376.
63.Stayman, An, Nogueira, RG, Gupta, R. A systematic review of stenting and angioplasty of symptomatic extracranial vertebral artery stenosis. Stroke 2011; 42:2212–2216.
64.Dorros, G, Lewin, RF, Jamnadas, P, Mathiak, LM. Peripheral transluminal angioplasty of the subclavian and innominate arteries utilizing the brachial approach: acute outcome and follow-up. Cathet Cardiovasc Diagn 1990;19: 71–76.
65.Hebrang, A, Maskovic, J, Tomac, B. Percutaneous transluminal angioplasty of the subclavian arteries: long-term results in 52 patients. AJR Am J Roentgenol 1991;156: 1091–1094.
66.Millaire, A, Trinca, M, Marache, P et al. Subclavian angioplasty: immediate and late results in 50 patients. Cathet Cardiovasc Diagn 1993;29: 8–17.
67.Motarjeme, A, Keifer, JW, Zuska, AJ, Nabawi, P. 1985. Percutaneous transluminal angioplasty for treatment of subclavian steal. Radiology 1985; 155: 611–613.
68.Meyers, PM, Schumacher, HC, Tanji, K, Higashida, RT, Caplan, LR. Use of stents to treat intracranial cerebrovascular disease. Annu Rev Med 2007;58:107–122.
69.Sundt, TM, Smith, HC, Campbell, JK et al. Transluminal angioplasty for basilar artery stenosis. Mayo Clin Proc 1980;55:673–680.
70.Piepgras, DG, Sundt, TM, Forbes, GS, Smith, HC. Balloon catheter transluminal angioplasty for vertebrobasilar ischemia. In Berguer, R, Bauer, R (eds.), Vertebrobasilar arterial occlusive disease. Raven Press, New York, 1984, pp. 215–224.
71.Gress, DR, Smith, WS, Dowd, CF et al. Angioplasty for intracranial symptomatic vertebrobasilar ischemia. Neurosurgery 2002;51:23–27.
72.Gomez, CR, Misra, VK, Liu, MW et al. Elective stenting of symptomatic basilar artery stenosis. Stroke 2000;31:95–99.
73.Yu, W, Smith, WS, Singh, V et al. Long-term outcome of endovascular stenting for symptomatic basilar artery stenosis. Neurology 2005; 64:1055–1057.
74.Kessler, IM, Mounayer, C, Piotin, M et al. The use of balloon-expandable stents in the treatment of intracranial arterial diseases: a 5 year single-center experience. AJNR Am J Neuroradiol 2005; 26: 2342–2348.
75.Henkes, H, Miloslavaski, E, Lowens, S et al. Treatment of intracranial atherosclerotic stenoses with balloon dilatation and self-expanding stent deployment (WingSpan). Neuroradiology 2005; 47: 222–228.
76.Bose, A, Hartmann, M, Henkes, H et al. A novel, self-expanding nitinol stent in medically refractory intracranial atherosclerotic stenoses. The Wingspan Study. Stroke 2007;38:1531–1537.
77.Groschel, K, Schnaudigel, S, Pilgram, SM, Wasser, K, Kastrup, A. A systematic review on outcome after stenting for intracranial atherosclerosis. Stroke 2009;40:e340–e347.
78.Chimowitz, MI, Lynn, MJ, Derdeyn, CP et al. for the SAMMPRIS Investigators. Stenting versus Aggressive Medical Therapy for intracranial Arterial Stenosis. N Engl J Med 2011;365:993–1003.
79.Fiorella, D, Derdeyn, CP, Lynn, MJ et al. for the SAMMPRIS Trial Investigators. Detailed analysis of periprocedural strokes in patients undergoing intracranial stenting in Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS). Stroke 2012;43:2682–2688.
80.Derdeyn, CP, Fiorella, D, Lynn, MJ et al. for the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators. Mechanisms of stroke after intracranial angioplasty and stenting in the SAMMPRIS Trial. Neurosurgery 2013;72:777–795.
81.Jiang, WJ, Srivastava, T, Gao, F, Du, B, Dong, KH, Xu, XT. Perforator stroke after elective stenting of symptomatic intracranial stenosis. Neurology 2006;66:1868–1872.
82.Jiang, W-J, Du, B, Hon, SF et al. Do patients with basilar or vertebral artery stenosis have a higher stroke incidence poststenting. J Neurointervent Surg 2010;2:50–54.
83.The EC-IC Bypass Study Group. Failure of the extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. N Engl J Med 1985;313:1191–1200.
84.Bloom, AL, Thomas, DP. Haemostasis and thrombosis. Churchill-Livingstone, Edinburgh, 1987.
85.del Zoppo, GJ. Vascular hemostasis and brain embolism. In Caplan, LR, Manning, WJ (eds.), Brain embolism. Informa Healthcare, New York, 2006, pp. 243–258.
86.Francis, CW, Kaplan, KL. Principles of antithrombotic therapy. In Lichtman, MA, Kipps, TJ, Kaushansky, K, Beutler, E, Seligsohn, U, Prchal, JT (eds.), Williams hematology. McGraw-Hill, New York, 2006, pp. 283–300.
87.Hemker, HC, Lindhout, T. Interaction of platelet activation and coagulation. In Fuster, V, Topol, EJ, Nabel, EG (eds.), Atherothrombosiss and coronary artery disease, 2nd edition. Lippincott Williams & Wilkins, Philadelphia, 2005, pp. 569–581.
88.Ogata, J. Heart and vessel pathology in 142 stroke patients. Ann Neurol 2008;63:770–781.
89.Marder, VJ, Chute, DJ, Starkman, S et al. Analysis of thrombi retrieved from cerebral arteries of patients with acute ischemic stroke. Stroke 2006; 37: 2086–2093.
90.Liebeskind, DS, Sanossian, N, Young, WH et al. CT and MRI vessel signs reflect clot composition uin acute stroke. Stroke 2011;42:1237–1247.
91.Di Nisio, M, Middledorp, S, Buller, H. Direct thrombin inhibitors. N Engl J Med 2005; 353:1028–1040.
92.Bauer, KA. New anticoagulants: anti IIa vs anti Xa–is one better? J Thromb Thrombolysis 2006; 21:67–72.
93.Connolly, SJ, Ezekowitz, MD, Yusuf, S et al. and the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–1151.
94.Granger, CB, Alexander, JH, McMurray, JJV et al. for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–992.
95.Patel, MR, Mahaffey, KW, Garg, J et al. and the ROCKET AF Steering Committee for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–891.
96.Nurden, AT. Platelet function and pharmacology of antiplatelet drugs. Cerebrovasc Dis 1997; 7(Suppl 6): 2–9.
97.Weksler, B. Antiplatelet agents in stroke prevention. Cerebrovasc Dis 2000; 10(Suppl 5): 41–48.
98.Caplan, LR. Antiplatelet therapy in stroke: present and future. Cerebrovasc Dis 2006; 21 (Suppl 1): 1–6.
99.Sacco, RL, Sivenius, J, Diener, H-C. Efficacy of aspirin plus extended- release dipyridamole in preventing recurrent stroke in high-risk populations. Arch Neurol 2005; 62:403–408.
100.Kwon, SU, Cho, Y-J, Koo, J-S et al. Cilostazol prevents the progression of the symptomatic intracranial stenosis. The multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 2005; 36:782–786.
101.Ameriso, S, lagos, R, Ferreira, LM et al. Cerebrovascular effects of cilostazol in patients with atherosclerotic disease. J Stroke Cerebrovasc Dis 2006; 15:273–276.
102.Tcheng, JE. Differences among the parenteral glycoprotein IIb/IIIa inhibitors and implications for treatment. Am J Cardiol 1999; 83:7E–15E.
103.Lefkovits, J, Plow, EF, Topol, EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332:1553–15559.
104.ESPS Group. European Stroke Prevention Study (ESPS): principal endpoints. Lancet 1987; 2:1351–1354.
105.Sivenius, J, Riekkinen, PJ, Smets, P, Laakso, M, Lowenthal, A. The European Stroke Prevention Study (ESPS): results by arterial distribution. Ann Neurol 1991;29:596–600.
106.Chimowitz, MI, Kokkinos, J, Strong, J et al. for the Warfarin-Aspirin Symptomatic Intracranial Disease Study Group. Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology 1995;45: 1488–1493.
107.Chimowitz, MI, Lynn, MJ, Howlett-Smith, H et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352:1305–1316.
108.Kasner, SE, Lynn, MJ, Chimowitz, MB et al. for the Warfarin Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators. Warfarin vs aspirin for symptomatic intracranial stenosis: subgroup analyses from WASID. Neurology 2006;67:1275–1278.
109.Koroshetz, W. Warfarin, aspirin, and intracranial vascular disease. N Engl J Med 2005;352:1368–1370.
110.Mohr, JP, Thompson, JLP, Lazar, RM et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444–1451.
111.Sacco, RL, Prabhakaran, S, Thompson, JL et al. for the WARSS investigators. Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death: subgroup analyses from the Warfarin-Aspirin Recurrent Stroke Study. Cerebrovasc Dis 2006; 22:4–12.
112.Wong, KS, Chen, C, Ng, PW et al. for the FISS-tris Study Investigators. Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study. Lancet Neurol 2007;6:407–413.
113.Wong, QS, Chen, C, Chen, XY et al. Low-molecular-weight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease. Subgroup analyses from the Fraxiparin in Stroke Study for the treatment of Ischemic Stroke (FISS-tris) Study. Stroke 2012:43:346–349.